{
    "organizations": [],
    "uuid": "bc359efb897105e464e701a63ce0b5adfdd0d3a1",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cynata-therapeutics-says-fda-grant/brief-cynata-therapeutics-says-fda-grants-orphan-drug-designation-to-cymerus-msc-product-cyp-001-idUSASC09TYE",
    "ord_in_thread": 0,
    "title": "BRIEF-Cynata Therapeutics says FDA Grants orphan drug designation to cymerus msc product, cyp-001",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 28, 2018 / 12:20 PM / in a minute BRIEF-Cynata Therapeutics says FDA Grants orphan drug designation to cymerus msc product, cyp-001 Reuters Staff \nMarch 28 (Reuters) - Cynata Therapeutics Ltd: \n* FDA GRANTS ORPHAN DRUG DESIGNATION TO CYNATA’S LEAD CYMERUS™ MSC PRODUCT, CYP-001 \n* CYNATA THERAPEUTICS - U.S. FDA GRANTED CO ORPHAN DRUG DESIGNATION FOR CYP-001 FOR TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE Source text for Eikon: Further company coverage:",
    "published": "2018-03-28T15:17:00.000+03:00",
    "crawled": "2018-03-28T15:34:32.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "minute",
        "therapeutic",
        "say",
        "fda",
        "grant",
        "orphan",
        "drug",
        "designation",
        "cymerus",
        "msc",
        "product",
        "reuters",
        "staff",
        "march",
        "reuters",
        "cynata",
        "therapeutic",
        "ltd",
        "fda",
        "grant",
        "orphan",
        "drug",
        "designation",
        "cynata",
        "lead",
        "msc",
        "product",
        "cynata",
        "therapeutic",
        "fda",
        "granted",
        "co",
        "orphan",
        "drug",
        "designation",
        "treatment",
        "acute",
        "graft",
        "versus",
        "host",
        "disease",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}